Friday, August 22, 2014

Aurinia to begin lupus nephritis trial at end of April

Aurinia to begin lupus nephritis trial at end of April

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient at the end of April in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well capitalized […]

Novadaq rings NASDAQ opening bell

Novadaq rings NASDAQ opening bell

May 31, 2013 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ: TSX:NVD) president and CEO Arun Menawat rang the opening bell at the NASDAQ today to mark the company’s one-year anniversary of listing on the NASDAQ Global Market. Novadaq’s core SPY Imaging technology has been integrated into four commercial imaging systems: SPY Elite, PINPOINT, LUNA and FireFly. Each system has been specifically […]

BioLineRx pipeline returns to the winner’s circle

BioLineRx pipeline returns to the winner’s circle

April 30, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=GE9bX0zfyUA’]

Tweet After disappointing investors in March by terminating a Phase 2/3 clinical trial of an anti-psychotic drug candidate for the treatment of schizophrenia, BioLineRx (NASDAQ:BLRX; TASE:BLRX) bounced back in April, posting positive Phase 2a results with an oral treatment for inflammatory bowel disease (IBD). “BioLineRx is not a binary company, but has a broad and […]

D. Medical in worldwide OEM pact with Twobiens

D. Medical in worldwide OEM pact with Twobiens

May 14, 2012 by · Leave a Comment 

Tweet D. Medical Industries (NASDAQ, TASE:DMED) has entered into an original equipment manufacturer agreement with Twobiens, a leading South Korean supplier of diabetes treatment and drug delivery products, for the worldwide distribution of its Spring Universal Detach Detect Infusion Sets under Twobiens’ private label. The three-year agreement contains annual sales targets and minimum order quantities […]

D. Medical in strategic reorganization

D. Medical in strategic reorganization

March 22, 2012 by · Leave a Comment 

Tweet D. Medical Industries (NASDAQ, TASE:DMED) has initiated a strategic restructuring designed to focus its business on maximizing and realizing the value of the company’s novel technology and intellectual property by licensing and/or selling the technology, or part of it, to third parties. At the same time, D. Medical said it will continue to pursue […]

NASDAQ approves Novadaq listing

NASDAQ approves Novadaq listing

March 1, 2012 by · Leave a Comment 

Tweet The common shares of Novadaq Technologies (TSX:NDQ) have been approved for listing on the NASDAQ Global Market under the ticker symbol NVDQ, and the shares will begin trading today. “The United States represents the largest market opportunity for Novadaq’s products and as the awareness for SPY Imaging has grown, many in the U.S. have […]

TearLab to explore commercial partnership opportunities in Japan

TearLab to explore commercial partnership opportunities in Japan

February 23, 2012 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has entered into a consulting agreement with one of its directors, Dr. Adrienne Graves, who will oversee identifying and leading discussions with potential partners for the commercialization of the TearLab Osmolarity System in Japan. Dr. Graves has been a member of TearLab’s board since April 2005. She was CEO of Santen […]

D. Medical CEO interviewed on Bloomberg TV

D. Medical CEO interviewed on Bloomberg TV

February 6, 2012 by · Leave a Comment 

Tweet Efri Argaman, CEO of D. Medical Industries (NASDAQ, TASE:DMED), was interviewed today by Sara Eisen on Bloomberg Television’s “InsideTrack.” Mr. Argaman discussed a host of topics, ranging from the state of the U.S. diabetes market, regulatory oversight and D. Medical’s sales strategy in the U.S. Instead of setting up a direct and costly U.S. […]

D. Medical inks fifth U.S. distributor of diabetic infusion sets

D. Medical inks fifth U.S. distributor of diabetic infusion sets

January 25, 2012 by · Leave a Comment 

Tweet D. Medical Industries (NASDAQ, TASE:DMED) has signed a non-exclusive agreement with Solara Medical Supplies for the distribution of its Spring Universal Infusion Sets in the U.S. The accord has an initial term of two years, beginning with Solara’s initial order, and then automatically renewed for one-year periods. “We have been very pleased by the […]

D. Medical expands U.S. distribution of infusion sets

D. Medical expands U.S. distribution of infusion sets

January 17, 2012 by · Leave a Comment 

Tweet D. Medical Industries (NASDAQ, TASE:DMED) has signed a non-exclusive agreement with Better Living Now, expanding the distribution of its Spring Universal Infusion Sets in the U.S. “The signing of this, our fourth distribution agreement in the U.S., is a key milestone achievement for our company,” D. Medical CEO Efri Argaman said in a statement, […]

Next Page »

Email Newsletters with Constant Contact
Google+